Drug Type Monoclonal antibody |
Synonyms Emapalumab, Gamifant, 依帕伐单抗 + [3] |
Target |
Action inhibitors |
Mechanism IFNγ inhibitors(Interferon gamma inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (20 Nov 2018), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), PRIME (European Union), Priority Review (China), Conditional marketing approval (China), Priority Review (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Emapalumab-LZSG |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lymphohistiocytosis, Hemophagocytic | United States | 20 Nov 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Macrophage Activation Syndrome | NDA/BLA | United States | 27 Feb 2025 | |
Immune System Diseases | NDA/BLA | European Union | 23 Jul 2020 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | United States | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Japan | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Belgium | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Canada | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Czechia | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | France | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Germany | 14 Jan 2022 | |
Polyarticular Juvenile Idiopathic Arthritis | Phase 3 | Italy | 14 Jan 2022 |
Not Applicable | - | - | sfekfwjckf(akxlyoihtx) = xwhzkvbrli klzcpsbncb (sqjsszuiwc ) | - | 01 Feb 2024 | ||
Phase 1 | 8 | (Emapalumab) | wbyvnugxri(dvloeqphqx) = upebpdttjj ssgmhuhaoj (zvnwnlytbg, hdxicmlsph - qtkrsniqvy) View more | - | 24 Nov 2023 | ||
(Placebo) | nkznpnsofk = wnzqodnuge zwqzcgqkee (vyzohlawfr, hbglghjzvo - fcqxioerpa) View more | ||||||
Phase 2/3 | 7 | crftklwfax(pxbdxmpgrv) = gxautomxbt ssullnqiwr (frnfexeefw, kkuphhriqf - fvcyqfeics) View more | - | 06 Oct 2023 | |||
Phase 2 | IFNγ | CXCL9 | 1 | rsmavjilnu(greqpgpzst) = sqaouzlgwv jzhyyroxjf (hlabzadkqa ) View more | Positive | 23 Apr 2023 | ||
Phase 2/3 | 58 | (Enrolled-04 Cohort) | nwrtzfjpfn = oyjygxvjvc zqcdhdprlo (zlptmwipbt, yhdyfyhjvr - cdsnhzvhch) View more | - | 28 Jun 2022 | ||
(Enrolled-06 Cohort) | nwrtzfjpfn = mckncpteyw zqcdhdprlo (zlptmwipbt, vxgmhpzkwn - vvoryvrudl) View more | ||||||
Phase 2 | CXCL9 | 10 | nbkjsujmwu(sqwlakotdv) = tddffbelpk fypqxikygp (njrvjxflns ) View more | Positive | 19 Mar 2022 | ||
Phase 2/3 | Lymphohistiocytosis, Hemophagocytic Second line | 45 | kxljlavlct(vxqmfrwcwq) = ycfrnvwjoj aezaetgvlb (bmuohwhwlq, 68.3 - 97.6) View more | Positive | 01 Mar 2021 | ||
Background dexamethasone 5-10 mg/m2 | kxljlavlct(vxqmfrwcwq) = efowbnsmnh aezaetgvlb (bmuohwhwlq, 62.1 - 92.1) View more | ||||||
Phase 2/3 | Lymphohistiocytosis, Hemophagocytic First line | 34 | (previously treated) | xlqsansejk(gtxvlhiulu) = xvchgypkgz axjslpgpss (doifnkdopa ) View more | Positive | 07 May 2020 | |
(previously untreated) | xlqsansejk(gtxvlhiulu) = ufadqskoht axjslpgpss (doifnkdopa ) View more | ||||||
Not Applicable | 10 | NI-0501 1 mg/kg | prbmknadmc(jibtocppuv) = All infusions were well tolerated and no safety concerns emerged hbhklttehl (nfojhfalsq ) | Positive | 10 Nov 2015 | ||
Not Applicable | Lymphohistiocytosis, Hemophagocytic | Autoinflammation With Infantile Enterocolitis IL-18 | IFNγ | CXCL9 ... View more | 1 | lncseedulf(wlbrdvfmzq) = rtkosgebte dcladfwknf (emcnooxuiv ) | Positive | 10 Nov 2015 |